2021
DOI: 10.3390/cancers13092247
|View full text |Cite
|
Sign up to set email alerts
|

Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma

Abstract: Few studies exist on the relationship between post-progression survival (PPS) and skeletal muscle volume in hepatocellular carcinoma (HCC) patients receiving sorafenib. This study aimed to analyze the effects of muscle volume on clinical outcomes. We retrospectively enrolled 356 HCC patients. Various clinical parameters, including skeletal muscle index, were analyzed as predictors of overall survival (OS), progression-free survival (PFS), and PPS. Patients with high muscle volume showed longer survival or PPS … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
23
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

2
3

Authors

Journals

citations
Cited by 9 publications
(23 citation statements)
references
References 46 publications
0
23
0
Order By: Relevance
“…In addition, HAIC might be considered as a frontline treatment choice in patients with macrovascular invasion without EHS or with Child-Pugh class B, regardless of skeletal MM [39-44, 53, 54]. Although it has been reported that the assessment of skeletal MM at the time of disease progression (so-called before post-sorafenib therapy) was significantly associated with PPS [30], we demonstrated that patients with high MM before sorafenib therapy was a significant favorable predictor of PPS [31]. We consider that the assessment of skeletal MM before post-sorafenib therapy is not essential to predict PPS.…”
Section: Management Of Sorafenib Based On An Assessment Of Skeletal MMmentioning
confidence: 78%
See 4 more Smart Citations
“…In addition, HAIC might be considered as a frontline treatment choice in patients with macrovascular invasion without EHS or with Child-Pugh class B, regardless of skeletal MM [39-44, 53, 54]. Although it has been reported that the assessment of skeletal MM at the time of disease progression (so-called before post-sorafenib therapy) was significantly associated with PPS [30], we demonstrated that patients with high MM before sorafenib therapy was a significant favorable predictor of PPS [31]. We consider that the assessment of skeletal MM before post-sorafenib therapy is not essential to predict PPS.…”
Section: Management Of Sorafenib Based On An Assessment Of Skeletal MMmentioning
confidence: 78%
“…Sorafenib was approved as a first-line systemic therapy for advanced HCC in 2007 [ 20 ]. Most previous studies have only evaluated skeletal MM without assessing HGS in patients with HCC treated with sorafenib [ 10 , 11 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ]. As shown in Table 1 , skeletal muscle depletion (low MM) is a poor prognostic factor for OS in most studies [ 10 , 22 , 23 , 24 , 26 , 28 , 31 , 32 ], while there was no significant difference in others [ 11 , 27 , 29 ].…”
Section: Impact Of Skeletal MM On Survival Among Patients Treated Wit...mentioning
confidence: 99%
See 3 more Smart Citations